Notably, the frequency of IL-17+ CD4+ cells exposed to CM was increased both in HCC patients (from 2.03 ± 0.23% to 9.04 ± 0.52%, P < 0.01) and in hemangiomas patients (from 1.96 ± 0.25% to 7.02 ± 0.37%, P < 0.01). Here, CD4 is linked to hepatocellular carcinoma.